These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27251414)

  • 1. Preparation and Characterization of Gelonin-Melittin Fusion Biotoxin for Synergistically Enhanced Anti-Tumor Activity.
    Shin MC; Min KA; Cheong H; Moon C; Huang Y; He H; Yang VC
    Pharm Res; 2016 Sep; 33(9):2218-2228. PubMed ID: 27251414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy.
    Ham S; Min KA; Yang JW; Shin MC
    Arch Pharm Res; 2017 Sep; 40(9):1094-1104. PubMed ID: 28900896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity.
    Shin MC; Zhang J; David AE; Trommer WE; Kwon YM; Min KA; Kim JH; Yang VC
    J Control Release; 2013 Nov; 172(1):169-178. PubMed ID: 23973813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment.
    Shin MC; Min KA; Cheong H; Moon C; Huang Y; He H; Yang VC
    Int J Pharm; 2017 May; 524(1-2):101-110. PubMed ID: 28359823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant TAT-gelonin fusion toxin: synthesis and characterization of heparin/protamine-regulated cell transduction.
    Shin MC; Zhao J; Zhang J; Huang Y; He H; Wang M; Min KA; Yang VC
    J Biomed Mater Res A; 2015 Jan; 103(1):409-419. PubMed ID: 24733757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin.
    Rosenblum MG; Cheung LH; Liu Y; Marks JW
    Cancer Res; 2003 Jul; 63(14):3995-4002. PubMed ID: 12873997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular tumor targeting of gelonin by fusion with F3 peptide.
    Ham SH; Min KA; Shin MC
    Acta Pharmacol Sin; 2017 Jun; 38(6):897-906. PubMed ID: 28414205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
    Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.
    Shin MC; Zhang J; Ah Min K; Lee K; Moon C; Balthasar JP; Yang VC
    J Control Release; 2014 Nov; 194():197-210. PubMed ID: 25204286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy.
    Liu M; Wang H; Liu L; Wang B; Sun G
    J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic engineering and characterisation of chlorotoxin-fused gelonin for enhanced glioblastoma therapy.
    Park T; Min KA; Cheong H; Moon C; Shin MC
    J Drug Target; 2019 Nov; 27(9):950-958. PubMed ID: 30156929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and functional characterization of human vascular endothelial growth factor-melittin fusion protein with analysis of the antitumor activity in vitro and in vivo.
    Wang D; Hu L; Su M; Wang J; Xu T
    Int J Oncol; 2015 Sep; 47(3):1160-8. PubMed ID: 26166416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
    Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
    Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of Recombinant Gelonin Using an Automated Liquid Chromatography System.
    Berstad MEB; Cheung LH; Weyergang A
    Toxins (Basel); 2020 Aug; 12(8):. PubMed ID: 32823678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Truncations of gelonin lead to a reduction in its cytotoxicity.
    Li Z; Qu Y; Li H; Yuan J
    Toxicology; 2007 Mar; 231(2-3):129-36. PubMed ID: 17222956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-hepatocarcinoma effect of recombinant adenovirus carrying melittin gene].
    Ling CQ; Li B; Zhang C; Gu W; Li SX; Huang XQ; Zhang YN
    Zhonghua Gan Zang Bing Za Zhi; 2004 Dec; 12(12):741-4. PubMed ID: 15619342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency.
    Yuan X; Lin X; Manorek G; Howell SB
    BMC Cancer; 2011 Feb; 11():61. PubMed ID: 21303546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wortmannin, a phosphoinositide 3-kinase inhibitor, selectively enhances cytotoxicity of receptor-directed-toxin chimeras in vitro and in vivo.
    Davol PA; Bizuneh A; Frackelton AR
    Anticancer Res; 1999; 19(3A):1705-13. PubMed ID: 10470104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C- versus N-terminally linked melittin-polyethylenimine conjugates: the site of linkage strongly influences activity of DNA polyplexes.
    Boeckle S; Wagner E; Ogris M
    J Gene Med; 2005 Oct; 7(10):1335-47. PubMed ID: 15945120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of hepatoma tumor growth by systemic administration of the phytotoxin gelonin driven by the survivin promoter.
    Wang Z; Zhou X; Li J; Liu X; Chen Z; Shen G; Guan T; Ye N; Wei X; Huang N; Yang L; Wei Y; Li J
    Neoplasma; 2013; 60(5):469-79. PubMed ID: 23790164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.